Sorkine P, Setton A, Halpern P, Miller A, Rudick V, Marmor S, Klausner J M, Goldman G
Department of Intensive Care and Anesthesiology, Ichilov Hospital, Tel Aviv Sourasky Medical Center, Israel.
Crit Care Med. 1995 Aug;23(8):1377-81. doi: 10.1097/00003246-199508000-00011.
To evaluate the possible role of tumor necrosis factor (TNF) in the development of lung injury after bowel ischemia, and the ability of TNF-soluble receptors to negate TNF toxicity, using a rat small bowel ischemia and reperfusion model.
Prospective, randomized, controlled laboratory study.
Research laboratory.
Forty adult male Sprague-Dawley rats weighing approximately 300 g.
The rats were divided equally into four groups: a) ischemia and reperfusion alone; b) those animals receiving TNF antibodies (1 mL) before reperfusion; and c) those animals receiving 200 micrograms of human recombinant TNF soluble receptors. These 30 anesthetized rats underwent 60 mins of superior mesenteric artery occlusion per 4 hrs of reperfusion. The remaining ten animals were sham operated (laparotomy), serving as controls. Lung permeability was measured using bovine serum albumin labeled with 125I, and organ injury was assessed histologically.
Thirty and 60 mins after declamping and reperfusion, plasma TNF concentrations increased to 830 +/- 66 and 173 +/- 56 pg/mL, respectively, compared with 10 pg/mL before ischemia (p < .001). In sham-operated control rats, TNF concentrations did not increase from baseline concentrations. Four hours after reperfusion, sequestration of neutrophils in the pulmonary microcirculation was noted (319 +/- 60 vs. 84 +/- 13 neutrophils/10 high-power fields in sham-operated rats [p < .04]). Pulmonary microvascular leak also occurred, as measured by translocation of radiolabeled albumin into the bronchoalveolar space and expressed as the ratio of bronchoalveolar lavage to blood concentrations. This ratio was 5.3 +/- 0.8 in ischemic control animals compared with 1.1 +/- 0.3 in sham animals (p < .03). Treatment with antibodies to TNF before reperfusion attenuated the pulmonary injury (75 +/- 6 neutrophils/10 high-power fields, permeability index 1.6 +/- 0.1) less than in ischemic controls (p < .005). A similar protection was achieved with soluble TNF receptors, which prevented bowel ischemia-induced lung neutrophil sequestration (117 +/- 35 neutrophils/10 high-power fields, pulmonary vascular leak ratio of 2.3 +/- 0.1, p < .05).
The results of this study show that ischemia and subsequent reperfusion of the intestine in rats produce lung injury. This injury is mediated, at least in part, by TNF. Soluble TNF receptors are an effective tool in preventing lung TNF injury after intestinal ischemia.
利用大鼠小肠缺血再灌注模型,评估肿瘤坏死因子(TNF)在肠缺血后肺损伤发生过程中的可能作用,以及TNF可溶性受体对抗TNF毒性的能力。
前瞻性、随机、对照实验室研究。
研究实验室。
40只体重约300g的成年雄性Sprague-Dawley大鼠。
将大鼠平均分为四组:a)单纯缺血再灌注组;b)再灌注前接受TNF抗体(1mL)的动物组;c)接受200微克重组人TNF可溶性受体的动物组。这30只麻醉大鼠每4小时进行60分钟的肠系膜上动脉阻断及再灌注。其余10只动物行假手术(剖腹术)作为对照。用125I标记的牛血清白蛋白测量肺通透性,并通过组织学评估器官损伤。
松开阻断夹并再灌注30分钟和60分钟后,血浆TNF浓度分别升至830±66和173±56pg/mL,而缺血前为10pg/mL(p<0.001)。假手术对照大鼠的TNF浓度未从基线浓度升高。再灌注4小时后,观察到肺微循环中有中性粒细胞滞留(319±60对假手术大鼠的84±13个中性粒细胞/10个高倍视野[p<0.04])。肺微血管渗漏也发生了,通过放射性标记白蛋白向支气管肺泡腔移位来测量,并表示为支气管肺泡灌洗与血液浓度之比。缺血对照动物组的该比值为5.3±0.8,而假手术动物组为1.1±0.3(p<0.03)。再灌注前用TNF抗体治疗减轻了肺损伤(75±6个中性粒细胞/10个高倍视野;通透性指数为l.6±0.1),但减轻程度小于缺血对照组(p<0.005)。可溶性TNF受体也获得了类似的保护作用,可防止肠缺血诱导的肺中性粒细胞滞留(117±35个中性粒细胞/10个高倍视野;肺血管渗漏率为2.3±0.1,p<0.05)。
本研究结果表明,大鼠肠道缺血及随后的再灌注会导致肺损伤。这种损伤至少部分是由TNF介导的。可溶性TNF受体是预防肠缺血后肺TNF损伤的有效工具。